Annexon (NASDAQ: ANNX) plans 2026 neuroinflammatory program milestones

Rhea-AI Filing Summary

Annexon, Inc. filed a current report stating that on January 12, 2026 it issued a press release titled “Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026.” The release outlines the company’s 2026 strategic priorities and key milestones for its lead programs on a targeted immunotherapy platform focused on neuroinflammatory diseases. The press release is included as Exhibit 99.1 and incorporated by reference, indicating that the main details about the planned registrational milestones in 2026 are contained in that exhibit.

false 0001528115 0001528115 2026-01-12 2026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

ANNEXON, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39402		27-5414423
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1400 Sierra Point Parkway, Bldg C, Suite 200 Brisbane, California		94005
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (650) 822-5500

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ANNX		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On January 12, 2026, Annexon, Inc. issued a press release titled “Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026” announcing its 2026 strategic priorities and key milestones for its lead programs. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated January 12, 2026, titled “Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026”.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Annexon, Inc.
Date: January 12, 2026				By:		/s/ Jennifer Lew
						Jennifer Lew
						Executive Vice President and Chief Financial Officer

FAQ

What did Annexon (ANNX) report in this Form 8-K?

Annexon, Inc. reported that it issued a press release on January 12, 2026 describing its 2026 strategic priorities and key milestones for its lead programs.

What is the focus of Annexon (ANNX)'s 2026 strategic priorities?

The 2026 strategic priorities focus on accelerating its next generation targeted immunotherapy platform for the treatment of neuroinflammatory diseases, with multiple registrational milestones in 2026.

Which diseases are targeted by Annexon (ANNX)'s platform mentioned in the filing?

The platform described in the January 12, 2026 press release is aimed at the treatment of neuroinflammatory diseases.

Where can investors find the detailed 2026 milestones for Annexon (ANNX)?

Detailed information is contained in the press release filed as Exhibit 99.1, which is incorporated by reference into the report.

Does this Annexon (ANNX) 8-K discuss financial results?

The report describes a press release on strategic priorities and milestones for lead programs; it does not discuss financial results.

What exhibits are included with this Annexon (ANNX) 8-K filing?

The filing includes Exhibit 99.1, the January 12, 2026 press release, and Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document.